IDEXX Laboratories, Inc.

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
496.5 ^USD	-0.61%		+2.71%	-10.55%

07-16	Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating	MT
06-24	Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $520	MT

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) added to S&P 500 Health Care Equipment & Services (Industry Group)

January 05, 2017 at 05:00 am

Latest news about IDEXX Laboratories, Inc.

Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating	07-16	MT
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $520	06-24	MT
Transcript : IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference, May-29-2024 10:55 AM	05-29
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620	05-14	MT
BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653	05-02	MT
Goldman Sachs Adjusts Price Target on IDEXX Laboratories to $600 From $675	05-02	MT
Stifel Adjusts Price Target on IDEXX Laboratories to $520 From $570	05-02	MT
Barclays Adjusts Price Target on IDEXX Laboratories to $570 From $655	05-02	MT
Redburn Atlantic Adjusts Price Target on IDEXX Laboratories to $500 From $460	05-02	MT
Wall Street: heaviness prevails after a volatile episode	05-01	CF
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.	05-01	CI
IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Transcript : IDEXX Laboratories, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
IDEXX Laboratories' Q1 Earnings, Revenue Increase	05-01	MT
Earnings Flash (IDXX) IDEXX LABORATORIES Posts Q1 Revenue $964.1M, vs. Street Est of $965.8M	05-01	MT
Idexx Laboratories, Inc. Revises Earnings Guidance for 2024	05-01	CI
North American Morning Briefing : Traders Wait for -2-	05-01	DJ
BofA Securities Cuts Price Target on IDEXX Laboratories to $595 From $600, Maintains Neutral Rating	04-30	MT
Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	04-01	MT
Elanco appoints two directors after settling with activist Ancora	04-01	RE
Elanco appoints two directors to its board after agreement with Ancora	04-01	RE
Idexx Laboratories: Superior growth prospects	03-11
Idexx Laboratories Insider Sold Shares Worth $790,427, According to a Recent SEC Filing	03-07	MT
Idexx Laboratories Insider Sold Shares Worth $4,525,596, According to a Recent SEC Filing	03-07	MT
Transcript : IDEXX Laboratories, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 11:00 AM	03-04

Chart IDEXX Laboratories, Inc.

Duration

Period

More charts

IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.6%); - water quality analysis (4.6%); - veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.5%). Net sales by source of income break down between product sales (57.1%) and services (42.9%). Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company